Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nelson L Michael

Showing results (281-290 of 372) with videos related to

Pageof 38
Sort By:
Journal of Virology|January 12, 2018
HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and PhagocytosisSaintedym Wills, Kwan-Ki Hwang, Pinghuang Liu, et al.
The Lancet. Infectious Diseases|July 4, 2020
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trialKathryn E Stephenson, Chen Sabrina Tan, Stephen R Walsh, et al.
Plos One|January 31, 2020
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South AfricansLue Ping Zhao, Andrew Fiore-Gartland, Lindsay N Carpp, et al.
NPJ Vaccines|March 19, 2023
SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodiesShikha Shrivastava, Joshua M Carmen, Zhongyan Lu, et al.
Nature|June 30, 2016
Vaccine protection against Zika virus from BrazilRafael A Larocca, Peter Abbink, Jean Pierre S Peron, et al.
Plos Pathogens|May 31, 2023
Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall responseLaTonya D Williams, Xiaoying Shen, Sheetal S Sawant, et al.
Plos One|February 8, 2014
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infectionSusan Zolla-Pazner, Allan deCamp, Peter B Gilbert, et al.
Journal of Virology|August 17, 2012
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene familyMattia Bonsignori, Justin Pollara, M Anthony Moody, et al.
NPJ Vaccines|May 23, 2024
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapyBoris Julg, Kathryn E Stephenson, Frank Tomaka, et al.
The Journal of Infectious Diseases|March 23, 2017
Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy TrialSupachai Rerks-Ngarm, Punnee Pitisuttithum, Jean-Louis Excler, et al.
Pageof 38

Showing results (281-290 of 372) with videos related to

Sort By:
Pageof 38
Journal of Virology|January 12, 2018
HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and PhagocytosisSaintedym Wills, Kwan-Ki Hwang, Pinghuang Liu, et al.
The Lancet. Infectious Diseases|July 4, 2020
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trialKathryn E Stephenson, Chen Sabrina Tan, Stephen R Walsh, et al.
Plos One|January 31, 2020
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South AfricansLue Ping Zhao, Andrew Fiore-Gartland, Lindsay N Carpp, et al.
NPJ Vaccines|March 19, 2023
SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodiesShikha Shrivastava, Joshua M Carmen, Zhongyan Lu, et al.
Nature|June 30, 2016
Vaccine protection against Zika virus from BrazilRafael A Larocca, Peter Abbink, Jean Pierre S Peron, et al.
Plos Pathogens|May 31, 2023
Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall responseLaTonya D Williams, Xiaoying Shen, Sheetal S Sawant, et al.
Plos One|February 8, 2014
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infectionSusan Zolla-Pazner, Allan deCamp, Peter B Gilbert, et al.
Journal of Virology|August 17, 2012
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene familyMattia Bonsignori, Justin Pollara, M Anthony Moody, et al.
NPJ Vaccines|May 23, 2024
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapyBoris Julg, Kathryn E Stephenson, Frank Tomaka, et al.
The Journal of Infectious Diseases|March 23, 2017
Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy TrialSupachai Rerks-Ngarm, Punnee Pitisuttithum, Jean-Louis Excler, et al.
Pageof 38